Pancreatic cancer: A review and update

Clinical Journal of Oncology Nursing

Volumn 12, Issue 5, 2008, Pages 735-741

  Dunphy, Elizabeth Prechtel ^a  

^a PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; INCIDENCE; PANCREAS TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR; SURVIVAL RATE;

HUMANS; INCIDENCE; PANCREATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE;

EID: 58149308587     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/08.CJON.735-741     Document Type: Article

References (29)

1. American Cancer Society. (2008). Cancer facts and figures 2008. Atlanta, GA: Author.
2. Bauer, J., Capra, S., Battistutta, D., Davidson, W., & Ash, S. (2005). Compliance with nutrition prescription improves outcomes in patients with unresectable pancreatic cancer. Clinical Nutrition, 24(6), 998-1004.
3. Burris, H.A., III, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. Journal of Clinical Oncology, 15(6), 2403-2413.
4. th ed., pp. 1523-1551). Sudbury, MA: Jones and Bartlett.
5. Eli Lilly and Company. (2007). Gemcitabine [Package insert]. Indianapolis, IN: Author.
6. Ferrone, C.R., Finkelstein, D.M., Thayer, S.P., Muzikansky, A., Fernandez-del Castillo, C., & Warshaw, A.L. (2006). Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. Journal of Clinical Oncology, 24(18), 2897-2902.
7. Freelove, R., & Walling, A.D. (2006). Pancreatic cancer: Diagnosis and management. American Family Physician, 73(3), 485-492.
8. th ed.). Chicago: Springer Science and Business Media.
9. Heinemann, V., Labianca, R., Hinke, A., & Louvet, C. (2007). Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: Pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Annals of Oncology, 18(10), 1652-1659.
10. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M.J. (2008). Cancer statistics, 2008. CA: A Cancer Journal for Clinicians, 58(2), 71-96.
11. Kalser, M.H., & Ellenberg, S.S. (1985). Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Archives of Surgery, 120(8), 899-903.
12. Kim, H.J., Kim, M.H., Myung, S.J., Lim, B.C, Park, E.T., Yoo, K.S., et al. (1999). A new strategy for the application of CA 19-9 in the differentiation of pancreaticobiliary cancer: Analysis using a receiver operating characteristic curve. American Journal of Gastroenterology, 94(7), 1941-1946.
13. Ko, A.H., & Tempero, M.A. (2005). Treatment of metastatic pancreatic cancer. Journal of the National Comprehensive Cancer Network, 3(5), 627-636.
14. Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M.G., Andre, T., et al. (2005). Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology, 23(15), 3509-3516.
15. Montgomery, R.C., Hoffman, J.P., Riley, L.B., Rogatko, A., Ridge, J.A., & Eisenberg, B.L. (1997). Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas. Annals of Surgical Oncology, 4(7), 551-556.
16. Moore, M.J., Goldstein, D., Hamm, J., Figer, A., Hecht, J.R., Gallinger, S., et al. (2007). Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 25(15), 1960-1966.
17. Mulcahy, M.F., Wahl, A.O., & Small, W., Jr. (2005). The current status of combined radiotherapy and chemotherapy for locally advanced or resected pancreas cancer. Journal of the National Comprehensive Cancer Network, 3(5), 637-642.
18. National Comprehensive Cancer Network. (2008). Pancreatic adenocarcinoma: Practice guidelines in oncology [v.1.2008]. Retrieved August 26, 2008, from http://www.nccn.org/professionals/physician_gls/PDF/pancreatic.pdf
19. Neoptolemos, J.P., Stocken, D.D., Friess, H., Bassi, C., Dunn, J.A., Hickey, H., et al. (2004). A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. New England Journal of Medicine, 350(12), 1200-1210.
20. Nolan, M.T., Hodgin, M.B., Olsen, S.J., Coleman, J., Sauter, P.K., Baker, D., et al. (2006). Spiritual issues of family members in a pancreatic cancer chat room. Oncology Nursing Forum, 33(2), 239-244.
21. Oettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J., Ridwelski, K., et al. (2007). Adjuvant chemotherapy with gemcitabine versus observation in patients undergoing curative intent resection of pancreatic cancer: A randomized controlled trial. JAMA, 297(3), 267-277.
22. Regine, W.F., Winter, K.W., Abrams, R., Safran, H., Hoffman, J.P., Konski, A., et al. (2006). A phase III study of pre and post chemoradiation 5-FU vs. pre and post chemoradiation gemcitabine for postoperative adjuvant treatment of resected pancreatic adenocarcinoma. Journal of Clinical Oncology, 2006 ASCO Meeting Proceedings Part I, 24(18s), 4007s.
23. Riehl, M. (2007). Help your patient cope with pancreatic cancer. Nursing, 37(4), 54-57.
24. Rothenberg, M.L., Moore, M.J., Cripps, M.C., Andersen, J.S., Portenoy, R.K., Burris, H.A., III, et al. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Annals of Oncology, 7(4), 347-353.
25. nd annual meeting of the American Society of Clinical Oncology, 2006. Journal of the Pancreas, 7(4), 337-348.
26. Sauter, P.K., & Coleman, J. (1999). Pancreatic cancer: A continuum of care. Seminars in Oncology Nursing, 15(1), 36-47.
27. Tempero, M., Plunkett, W., Ruiz Van Haperen, V., Hainsworth, J., Hochster, H., Lenzi, R., et al. (2003). Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. Journal of Clinical Oncology, 21(18), 3402-3408.
28. Ujiki, M.B., & Talamonti, M.S. (2007). Guidelines for the surgical management of pancreatic adenocarcinoma. Seminars in Oncology, 34(4), 311-320.
29. Yeo, C.J., Yeo, T.P., Hruban, R., Kern, S.E., Iacobuzio-Donohue, C.A., Maitra, A., et al. (2005). Pancreas cancer. In V. Devita, S. Hellman, & S. Rosenberg (Eds.), Cancer: Principles and practice of oncology (7th ed., pp. 945-986). Philadelphia: Lippincott Williams and Wilkins.